ArticleStem cells translational medicine2025
Anti-fibrotic effect of human amniotic fluid stem cells in biliary epithelial-mesenchymal transition of liver ductal organoid.
Article in Stem cells translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Organoids in Pediatric Congenital Hepatobiliary Diseases: Current Status and Progress in Clinical Translational Research.Biomedicines · 2026Review
- NAD+ metabolic collapse and arrest of epithelial development in Hirschsprung disease.World journal of pediatric surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeIn biliary atresia (BA), it has been demonstrated that biliary epithelial-mesenchymal transition (EMT) of reactive ductular cells is associated with liver fibrosis. This study aimed to develop an ex vivo biliary EMT model of liver ductal organoids for exploring the involvement of biliary EMT in fibrogenesis and to investigate whether human amniotic fluid stem cells (hAFSCs) can mitigate the biliary EMT process.
methodsLiver ductal organoids were generated from the intrahepatic bile duct of healthy neonatal mice. Biliary EMT was induced in organoids by the administration of transforming growth factor beta-1 (TGF-β1) in culture medium. hAFSCs were co-cultured with organoids during biliary EMT induction. Expression of biliary epithelial cells, mesenchymal cells, myofibroblast, collagen I, and genes related to the Wnt signaling pathway were evaluated.
resultsFollowing administration of TGF-β1, we observed an increased expression of mesenchymal cell markers N-cadherin and Vimentin, as well as myofibroblast marker alpha-smooth muscle actin (α-SMA) in liver ductal organoids which were associated with increased expression of collagen 1. Administration of hAFSCs to organoids significantly attenuated TGF-β1-induced biliary EMT and collagen production. In addition, Wnt signaling was upregulated in biliary EMT, while hAFSCs downregulated the Wnt signaling resulting in decreased expression of myofibroblast and collagen in organoids.
conclusionTGF-β1 is a potent cytokine that induces biliary EMT. hAFSCs significantly mitigated TGF-β1-induced biliary EMT in liver ductal organoids. The beneficial effect of hAFSCs administration is associated with the downregulation of the Wnt signaling pathway. This study indicates that hAFSCs can prevent the progression of liver fibrosis in BA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.